- Home
- LUNG vs RIGL Comparison
LUNG vs RIGL Comparison
Compare LUNG & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- RIGL
- Stock Information
- Founded
- LUNG 1995
- RIGL 1996
- Country
- LUNG United States
- RIGL United States
- Employees
- LUNG N/A
- RIGL N/A
- Industry
- LUNG Industrial Specialties
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- LUNG Health Care
- RIGL Health Care
- Exchange
- LUNG Nasdaq
- RIGL Nasdaq
- Market Cap
- LUNG 248.0M
- RIGL 282.2M
- IPO Year
- LUNG 2020
- RIGL 2000
- Fundamental
- Price
- LUNG $6.45
- RIGL $15.25
- Analyst Decision
- LUNG Strong Buy
- RIGL Buy
- Analyst Count
- LUNG 7
- RIGL 4
- Target Price
- LUNG $13.71
- RIGL $31.13
- AVG Volume (30 Days)
- LUNG 210.4K
- RIGL 224.7K
- Earning Date
- LUNG 10-28-2024
- RIGL 11-05-2024
- Dividend Yield
- LUNG N/A
- RIGL N/A
- EPS Growth
- LUNG N/A
- RIGL N/A
- EPS
- LUNG N/A
- RIGL N/A
- Revenue
- LUNG $76,583,000.00
- RIGL $130,201,000.00
- Revenue This Year
- LUNG $22.73
- RIGL $38.26
- Revenue Next Year
- LUNG $19.02
- RIGL $24.21
- P/E Ratio
- LUNG N/A
- RIGL N/A
- Revenue Growth
- LUNG 26.26
- RIGL 7.48
- 52 Week Low
- LUNG $5.46
- RIGL $7.10
- 52 Week High
- LUNG $14.84
- RIGL $17.30
- Technical
- Relative Strength Index (RSI)
- LUNG 32.80
- RIGL 51.88
- Support Level
- LUNG $6.56
- RIGL $14.87
- Resistance Level
- LUNG $7.47
- RIGL $16.85
- Average True Range (ATR)
- LUNG 0.38
- RIGL 0.89
- MACD
- LUNG -0.22
- RIGL -0.19
- Stochastic Oscillator
- LUNG 2.76
- RIGL 35.96
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.